Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.41 |
| ▸ | GRM5 | P41594 | 4/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774252 | 0.93 | TLR7 (0.45) | TLR7GRM5TLR8 | |
| SCHEMBL10237194 | 0.93 | TLR7 (0.45) | TLR7GRM5TLR8 | |
| SCHEMBL1774499 | 0.90 | TLR7 (0.45) | TLR7GRM5TLR8 | |
| Hydrochloric Acid SCHEMBL1774944 | 0.89 | TLR7 (0.44) | TLR7GRM5TLR8 | |
| SCHEMBL1773746 | 0.88 | TLR7 (0.40) | TLR7TLR8 | |
| SCHEMBL1775916 | 0.87 | TLR7 (0.48) | TLR7GRM5TLR8 | |
| SCHEMBL2513479 | 0.84 | TLR7 (0.43) | TLR7TLR8 | |
| SCHEMBL1775037 | 0.83 | TLR7 (0.43) | TLR7TLR8 | |
| SCHEMBL1773748 | 0.83 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL2512590 | 0.81 | TLR7 (0.43) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207162-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-26 | — | — | US | claimed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | claimed |
| US-8546383-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546383-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546383-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-09-13 | — | — | US | disclosed |
| EP-1831226-B1 | CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1831226-B1 | CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8207162-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-7943609-B2 | Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides | 3M INNOVATIVE PROPRERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943609-B2 | Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides | 3M INNOVATIVE PROPRERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943609-B2 | Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides | 3M INNOVATIVE PROPRERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNAR1, IFNG, IL4 | TLR7 124/4885GRM5 2061/4885TLR8 409/4885 |
| US-20120232057-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | TLR7 132/4885GRM5 2138/4885TLR8 440/4885 |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | TLR7 124/4885GRM5 2061/4885TLR8 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.